Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat

Neuroscience

Volumn 220, Issue , 2012, Pages 291-301

  Sonia Angeline, M ^a   Chaterjee, P ^a   Anand, K ^a   Ambasta, R K ^a   Kumar, P ^a,b  

^a VIT UNIVERSITY   (India)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heat shock proteins (HSPs); Neurodegeneration; Parkin; Parkinson's disease (PD); Rotenone

Indexed keywords

CASPASE 3; CASPASE 9; DJ 1 PROTEIN; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; PARKIN; ROTENONE; SILVER; TYROSINE 3 MONOOXYGENASE; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; CELL DEATH; CELL STRUCTURE; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DIFFERENTIAL EXPRESSION; DOWN REGULATION; HISTOPATHOLOGY; HOMEOSTASIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOCOMOTION; MALE; MOLECULAR MECHANICS; MOTOR ACTIVITY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; STAINING; STRESS; SUBSTANTIA NIGRA; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CASPASES; FLUORESCENT ANTIBODY TECHNIQUE; HEAT-SHOCK PROTEINS; MALE; MENTAL DISORDERS; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; ROTENONE; TRANSCRIPTOME; UBIQUITIN-PROTEIN LIGASES; UNCOUPLING AGENTS;

EID: 84864759870     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.06.021     Document Type: Article

References (43)

1. Ambasta R.K., Schreiber J.G., Janiszewski M., Busse R., Brandes R.P. Noxa1 is a central component of the smooth muscle NADPH oxidase in mice. Free Radic Biol Med 2006, 41:193-201.
2. Barnéoud P., Mazadier M., Miquet J.M., Parmentier S., Dubédat P., Doble A., Boireau A. Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience 1996, 74:971-983.
3. Beal M.F. Experimental models of Parkinson's disease. Nat Rev Neuro 2001, 2:325-332.
4. Benn S.C., Woolf C.J. Adult neuron survival strategies-slamming on the brakes. Nat Rev Neurosci 2004, 5:686-700.
5. Bové J., Prou D., Perier C., Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005, 2(3):484-494.
6. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis 2009, 34:279-290.
7. Casarrubea M., Sorbera F., Santangelo A., Crescimanno G. Microstructure of rat behavioral response to anxiety in hole-board. Neurosci Lett 2010, 481:82-87.
8. Chung W.G., Miranda C.L., Maier C.S. Epigallocatechin gallate (EGCG) potentiates the cytotoxicity of rotenone in neuroblastoma SH-SY5Y cells. Brain Res 2007, 1176:133-142.
9. Cookson M.R., Bandmann O. Parkinson's disease: insights from pathways. Hum Mol Genet 2010, 19(R1):R21-R27.
10. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
11. Dedmon M.M., Christodoulou J., Wilson M.R., Dobson C.M. Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species. J Biol Chem 2005, 280:14733-14740.
12. Dominey P.F., Inui T. Cortico-striatal function in sentence comprehension: insights from neurophysiology and modeling. Cortex 2009, 45:1008-1012.
13. Dong Z., Wolfer D.P., Lipp H.P., Büeler H. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol Ther 2005, 11:80-88.
14. Fleming S.M., Zhu C., Fernagut P.O., Mehta A., DiCarlo C.D., Seaman R.L., Chesselet M.F. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 2004, 187:418-429.
15. Gandhi S., Wood N.W. Molecular pathogenesis of Parkinson's disease. Hum Mol Genet 2005, 14:2749-2755.
16. Haavik J., Toska K. Tyrosine hydroxylase and Parkinson's disease. Mol Neurobiol 1998, 16:285-309.
17. Hartl F.U. Molecular chaperones in cellular protein folding. Nature 1996, 381:571-579.
18. Hartley A., Stone J.M., Heron C., Cooper J.M., Schapira A.H. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 1994, 63:1987-1990.
19. Hegde A.N. Ubiquitin-proteasome-mediated local protein degradation and synaptic plasticity. Prog Neurobiol 2004, 73:311-357.
20. Hightower L.E. Heat shock, stress proteins, chaperones, and proteotoxicity. Cell 1991, 66:191-197.
21. Jankovic J., Aguilar L.G. Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat 2008, 4:743-757.
22. Jiang H., Ren Y., Zhao J., Feng J. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 2004, 13:1745-1754.
23. Joel D., Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 2000, 96:451-474.
24. Kumar P., Ambasta R.K., Veereshwarayya V., Rosen K.M., Kosik K.S., Band H., Mestril R., Patterson C., Querfurth H.W. CHIP and HSPs interact with beta-APP in a proteasome dependent manner and influence Abeta metabolism. Hum Mol Genet 2007, 16:848-864.
25. Kumar P., Pradhan K., Karunya R., Ambasta R.K., Querfurth H.W. Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders. J Neurochem 2012, 120:350-370.
26. Kumaran R., Vandrovcova J., Luk C., Sharma S., Renton A., Wood N.W., Hardy J.A., Lees A.J., Bandopadhyay R. Differential DJ-1 gene expression in Parkinson's disease. Neurobiol Dis 2009, 36(2):393-400.
27. Lapointe N., St-Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., Cicchetti F. Rotenone induces non-specific central nervous system and systemic toxicity. FASEBJ 2004, 18:717-719.
28. Luo G.R., Chen S., Le W.D. Are heat shock proteins therapeutic target for Parkinson's disease?. Int J Biol Sci 2006, 3:20-26.
29. Moore D.J., West A.B., Dawson V.L., Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005, 28:57-87.
30. Ni Z., Pinto A.D., Lang A.E., Chen R. Involvement of the cerebellothalamocortical pathway in Parkinson disease. Ann Neurol 2010, 68:816-824.
31. Pardridge W.M. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx 2005, 2:129-138.
32. Soldner F., Hockemeyer D., Beard C., Gao Q., Bell G.W., Cook E.G., Hargus G., Blak A., Cooper O., Mitalipova M., Isacson O., Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136:964-977.
33. Sowell R.A., Owen J.B., Butterfield D.A. Proteomics in animal models of Alzheimer's and Parkinson's diseases. Ageing Res Rev 2009, 8:1-17.
34. Stevenson J.K., Oishi M.M., Farajian S., Cretu E., Ty E., McKeown M.J. Response to sensory uncertainty in Parkinson's disease: a marker of cerebellar dysfunction?. Eur J Neurosci 2011, 33:298-305.
35. Switzer R.C. Application of silver degeneration stains for neurotoxicity testing. Toxicol Pathol 2000, 28:70-83.
36. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010, 37:510-518.
37. Tenkova T.I., Goldberg M.P. A modified silver technique (de Olmos stain) for assessment of neuronal and axonal degeneration. Methods Mol Biol 2007, 399:31-39.
38. Tsai Y.C., Fishman P.S., Thakor N.V., Oyler G.A. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem 2003, 278:22044-22055.
39. Uversky V.N. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 2004, 318:225-241.
40. Waza M., Adachi H., Katsuno M., Minamiyama M., Tanaka F., Doyu M., Sobue G. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J Mol Med (Berl) 2006, 84:635-646.
41. Xiong N., Huang J., Zhang Z., Zhang Z., Xiong J., Liu X., Jia M., Wang F., Chen C., Cao X., Liang Z., Sun S., Lin Z., Wang T. Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease. PLoS One 2009, 4:e7878.
42. Yang J., Sadler T.R., Givrad T.K., Maarek J.M., Holschneider D.P. Changes in brain functional activation during resting and locomotor states after unilateral nigrostriatal damage in rats. Neuroimage 2007, 36:755-773.
43. Zhou Y., Gu G., Goodlett D.R., Zhang T., Pan C., Montine T.J., Montine K.S., Aebersold R.H., Zhang J. Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem 2004, 279:39155-39164.